Invivyd, Inc. Q4 FY2025 earnings call

Marc Elia mentioned the Revolution clinical program is well underway, brought in a new Chief Medical Officer, commercial work with PEMGARDA showed growth, pre-commercial preparation for VYD2311, ongoing work with monoclonal antibodies among various groups, pipeline exploration in long COVID and post-vaccine syndrome, identification of a highly potent RSV antibody, and update on measles program expected in first half of year. Timothy Lee discussed commercial update on PEMGARDA, growth in utilization across specialties, building category with PEMGARDA, and preparation for VYD2311. William Duke touched on financial results with PEMGARDA revenue growth and cash position.

PEMGARDA net revenues continued to grow in the fourth quarter, up 31% over third quarter 2025 and up 25% over fourth quarter 2024. Full net revenues in 2025 totaled $53.4 million.

Declaration clinical trial reached target enrollment, anticipation of suitability for robust assessment of VYD2311 effectiveness around mid-year 2026, potential trial resizing in April depending on event rates, mid-year timing guidance for Declaration considered Q2 or Q3 2026.

Q: Patrick Trucchio asked about resizing decision criteria in Declaration program and secondary endpoints.

A: Marc Elia discussed resizing algorithms and secondary endpoints collection.

Q: Patrick Trucchio asked about measles antibody program use cases.

A: Marc Elia and Dr. Robert Allen discussed use cases like outbreak prophylaxis, bridge to vaccine, etc.

Q: Tom Schrader asked about trial sculpting and myocarditis monitoring.

A: Marc Elia talked about trial placement and myocarditis monitoring.

Q: Tom Schrader asked about RSV antibody.

A: Marc Elia and Dr. Robert Allen discussed RSV antibody properties and strategy.